Group 1: Company Developments - Iwubio has completed a clinical trial for its "Artemisia pollen allergen sublingual drops," demonstrating long-term efficacy and safety for adult patients with allergic rhinitis, providing evidence for clinical long-term use [1] - The company reported a net profit of 166 million to 181 million yuan for the first half of the year, representing a year-on-year growth of 16.96% to 27.56% [3] - Iwubio's product sales include 455 million yuan for dust mite drops, 21.02 million yuan for Artemisia pollen drops, and 6.32 million yuan for skin prick solution, with respective year-on-year growth rates of 10.51%, 71.37%, and 104.38% [3] Group 2: Market Position and Strategy - Iwubio is a leading player in the domestic desensitization treatment market, focusing on the development of allergen products and expanding into stem cell and natural medicine research [3][4] - The company has established a strong R&D team to enhance its innovation capabilities and maintain its market leadership [4] - Iwubio is the only company in China with two approved sublingual allergen desensitization products, providing a competitive edge in the desensitization treatment field [4] Group 3: Industry Trends - The global allergy treatment market is projected to reach 31.07 billion USD by 2029, with a compound annual growth rate of 8.10% from 2024 to 2029 [2] - The increasing prevalence of allergic diseases poses significant public health challenges, necessitating effective prevention and treatment strategies [2][6] - Iwubio aims to become an international leader in the pharmaceutical industry while ensuring long-term development and returns for shareholders and employees [6]